Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). 28 Jan Written By Carla Aguilera Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chi Fung Chan G, Ruud E, Schroeder H, Beck-Popovic M, Schreier G, Loibner H, Ambros P, Holmes K,Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.Cancers (Basel). 2020 Jan 28;12(2):309. doi: 10.3390/cancers12020309. PMID: 32013055; PMCID: PMC7072500. 2020 Carla Aguilera
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). 28 Jan Written By Carla Aguilera Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chi Fung Chan G, Ruud E, Schroeder H, Beck-Popovic M, Schreier G, Loibner H, Ambros P, Holmes K,Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.Cancers (Basel). 2020 Jan 28;12(2):309. doi: 10.3390/cancers12020309. PMID: 32013055; PMCID: PMC7072500. 2020 Carla Aguilera
